A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a First-in-Human, open-label, sequential dose-escalation and dose-expansion study of KD033 in adult subjects with advanced or metastatic solid tumors. The main purpose of this study is to test KD033 at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kadmon Corporation, LLC

Criteria

Inclusion Criteria:

1. Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.

2. Measurable disease per RECIST v1.1 guidelines.

3. Life expectancy of at least 3 months.

4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.

5. Adequate organ and bone marrow functions.

6. All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non significant or stable on supportive care.

7. All subjects, male and female, who are not surgically sterilized or postmenopausal must agree to use "highly effective methods of contraception" during the study and for at least 60 days after the last dose of KD033.

Exclusion Criteria:

1. Use of immunotherapy, biological therapy, cytokine therapy < 21 days prior to the first dose of study drug.

2. Use of immunomodulating agents < 21 days prior to the first dose of study drug.

3. Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy < 14 days prior to the first dose of study drug.

4. Anti PD-L1 or anti PD-1 therapy < 6 weeks prior to the first dose of study drug.

5. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.

6. Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment.

7. Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.

8. History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Subjects with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.

9. Receipt of any organ transplantation including hematopoietic cell transplantation.

10. Has a paraneoplastic syndrome of autoimmune nature.

11. History of interstitial lung disease or severe obstructive pulmonary disease.

12. Clinically significant cardiovascular/cerebrovascular disease.

13. QTc(F) interval > 450 ms for men or > 470 ms for women)

14. Left ventricular ejection fraction (LVEF) < 50% as measured by an echocardiogram (ECHO).

15. Active infection requiring therapy.

Other protocol-defined exclusion criteria could apply.